MRK catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
November 2026
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Nov 20, 2026Sponsor estimate | NCT04634877Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly...Merck Sharp & Dohme LLC · Endometrial Neoplasms | MRKLead | Phase 3 | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Nov 20, 2026Sponsor estimatePhase 3NCT04634877Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly...Merck Sharp & Dohme LLC · Endometrial NeoplasmsActive, not recruitingMRKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
December 2026
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Dec 31, 2026Sponsor estimate | NCT04255849Nine-valent HPV Vaccine to Prevent Persistent Oral HPV Infection in Men Living With HIVWeill Medical College of Cornell University · HPV Positive Oropharyngeal Squamous Cell Carcinoma | MRKCollaborator | Phase 3 | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Dec 31, 2026Sponsor estimatePhase 3NCT04255849Nine-valent HPV Vaccine to Prevent Persistent Oral HPV Infection in Men Living With HIVWeill Medical College of Cornell University · HPV Positive Oropharyngeal Squamous Cell CarcinomaActive, not recruitingMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
January 2027
- Primary completion Jan 12, 2027Sponsor estimatePhase 3NCT05609968Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With...Merck Sharp & Dohme LLC · Carcinoma, Non-Small-Cell LungActive, not recruitingMRKLeadGILDCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 15, 2027Sponsor estimatePhase 3NCT04199689Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged...Merck Sharp & Dohme LLC · Papillomavirus InfectionsActive, not recruitingMRKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 29, 2027Sponsor estimatePhase 3NCT05911295Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2Seagen, a wholly owned subsidiary of Pfizer · Urothelial CarcinomaActive, not recruitingPFELeadMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 31, 2027Sponsor estimatePhase 3NCT04241185Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder...Merck Sharp & Dohme LLC · Urinary Bladder NeoplasmsActive, not recruitingMRKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 6 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.